Molecular Partners Future Growth

Future criteria checks 3/6

Molecular Partners is forecast to grow earnings and revenue by 16.9% and 49% per annum respectively. EPS is expected to grow by 15.4% per annum. Return on equity is forecast to be 48.2% in 3 years.

Key information

16.9%

Earnings growth rate

15.35%

EPS growth rate

Biotechs earnings growth	25.1%
Revenue growth rate	49.0%
Future return on equity	48.23%
Analyst coverage	Low
Last updated	13 May 2026

Recent future growth updates

No updates

Recent updates

Seeking Alpha • Jan 15

Molecular Partners: Leveraging Its Biologics Platform Into Early Clinical Programs

Summary Molecular Partners AG leverages a novel DARPin platform for targeted cancer therapies, with promising early-stage candidates like MP0533 and MP0317 in clinical trials. Financially, MOLN has a cash runway of 2-2.5 years, but future funding remains uncertain, posing a risk for long-term sustainability. Strengths include innovative approaches and a diverse pipeline, but the lack of a clear frontrunner and early-stage focus are significant risks. Despite uncertainties, MOLN's valuation at $200 million presents a ground-floor investment opportunity, warranting a tentative “Buy” with awareness of inherent risks. Read the full article on Seeking Alpha

Seeking Alpha • Aug 07

Molecular Partners: A Speculative Bet On Innovative DARPin Technology

Summary Molecular Partners develops DARPin proteins for oncology and virology, offering advantages over traditional antibodies. The company's Switch-DARPin platform offers conditional and reversible immune activation, which benefits vulnerable populations needing targeted, customizable therapies. MOLN's pipeline includes MP0533, MP0621, and MP0317, with collaborations on MP0712 and other preclinical programs. MOLN trades at a $203.7 million market cap with significant cash reserves but faces high cash burn and potential future capital raises. Despite biotech risks, MOLN's highly differentiated IP and sufficient resources make it a speculative "buy" for investors interested in unique oncology and virology biotechs. Read the full article on Seeking Alpha

Seeking Alpha • Aug 25

Molecular Partners GAAP EPS of CHF4.59, revenue of CHF184.5M

Molecular Partners press release (NASDAQ:MOLN): 1H GAAP EPS of CHF4.59. Revenue of CHF184.5M (+4093.2% Y/Y). Strong financial position with CHF 285.1 million in cash (including short term deposits) as of June 30, 202. Company expected to be funded into 2026, excluding any potential payments from R&D partnerships.

Earnings and Revenue Growth Forecasts

NasdaqGS:MOLN - Analysts future estimates and past financials data (CHF Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2028	N/A	-55	-52	-43	2
12/31/2027	31	-23	15	15	4
12/31/2026	6	-55	-36	-21	4
3/31/2026	N/A	-58	-49	-48	N/A
12/31/2025	N/A	-62	-52	-51	N/A
9/30/2025	N/A	-60	-54	-53	N/A
6/30/2025	1	-65	-58	-57	N/A
3/31/2025	2	-59	-60	-59	N/A
12/31/2024	5	-54	-60	-59	N/A
9/30/2024	6	-63	-63	-62	N/A
6/30/2024	8	-58	-63	-62	N/A
3/31/2024	7	-59	-60	-60	N/A
12/31/2023	7	-62	-60	-59	N/A
9/30/2023	9	-60	-58	-57	N/A
6/30/2023	9	-62	-63	-62	N/A
3/31/2023	20	-50	-63	-62	N/A
12/31/2022	190	118	117	119	N/A
9/30/2022	189	117	112	114	N/A
6/30/2022	190	118	111	113	N/A
3/31/2022	182	106	101	102	N/A
12/31/2021	10	-64	-92	-91	N/A
9/30/2021	9	-67	-71	-69	N/A
6/30/2021	6	-72	-55	-54	N/A
3/31/2021	7	-66	-47	-46	N/A
12/31/2020	9	-63	-31	-29	N/A
9/30/2020	11	-53	-47	-45	N/A
6/30/2020	14	-48	-58	-56	N/A
3/31/2020	17	-43	-30	-28	N/A
12/31/2019	20	-36	N/A	-1	N/A
9/30/2019	17	-37	N/A	1	N/A
6/30/2019	14	-38	N/A	4	N/A
3/31/2019	12	-38	N/A	-19	N/A
12/31/2018	10	-37	N/A	-42	N/A
9/30/2018	17	-27	N/A	-41	N/A
6/30/2018	23	-18	N/A	-39	N/A
3/31/2018	22	-24	N/A	N/A	N/A
12/31/2017	20	-25	N/A	-40	N/A
9/30/2017	17	-26	N/A	N/A	N/A
6/30/2017	16	-28	N/A	-38	N/A
3/31/2017	19	-22	N/A	N/A	N/A
12/31/2016	23	-19	N/A	-35	N/A
9/30/2016	27	-13	N/A	N/A	N/A
6/30/2016	31	-3	N/A	18	N/A
3/31/2016	30	-2	N/A	N/A	N/A
12/31/2015	29	0	N/A	26	N/A
9/30/2015	28	-6	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MOLN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MOLN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MOLN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MOLN's revenue (49% per year) is forecast to grow faster than the US market (12.7% per year).

High Growth Revenue: MOLN's revenue (49% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MOLN's Return on Equity is forecast to be very high in 3 years time (48.2%).

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/06 17:42
End of Day Share Price	2026/07/02 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Molecular Partners AG is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Robert Burns	H.C. Wainwright & Co.
Richard Vosser	J.P. Morgan
Wei Chang	Leerink Partners LLC

Molecular Partners Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Recent updates

Molecular Partners Provides Update on Clinical Progress Across Pipeline of Darpin Radiotherapeutics

Molecular Partners And Orano Med Dose First Patients In Phase 1/2a Trial Of DLL3 Radio-DARPin MP0712

Molecular Partners Presents Three Posters At AACR 2026, with New Preclinical Data for First Switch-DARPin T Cell Engager MP0632 and DLL3 Radio-DARPin MP0712

Molecular Partners AG Announces Board and Committee Appointments

Molecular Partners Ag Announces That Current Board Member Steven H. Holtzman Will Not Stand for Re-Election

Molecular Partners AG, Annual General Meeting, Apr 14, 2026

Molecular Partners AG Presents New Preclinical Data Highlighting Radio-DARPins’ Amenability To Multiple Isotopes

Molecular Partners AG to Report First Half, 2026 Results on Aug 25, 2026

Molecular Partners AG Announces Formation of Scientific Advisory Board for Radiopharmaceuticals

Molecular Partners AG Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025

Molecular Partners AG to Report Fiscal Year 2025 Results on Mar 12, 2026

Molecular Partners AG Announces Appointment of Martin Steegmaier, Ph.D. as Chief Scientific Officer and Member of Executive Committee, Effective October 1, 2025

Molecular Partners and Orano Med Present Preclinical Data on Mesothelin-Targeting Radio-DARPin Candidate MP0726 at SNMMI 2025

Molecular Partners AG Presents Positive Data from Ongoing Phase 1/2a Trial of MP0533 in AML at EHA 2025

Molecular Partners AG Presents New Preclinical Data on Radio-DARPin and Switch-DARPin Programs at AACR 2025

Molecular Partners AG, Annual General Meeting, Apr 16, 2025

Molecular Partners AG to Report First Half, 2025 Results on Aug 25, 2025

Molecular Partners: Leveraging Its Biologics Platform Into Early Clinical Programs

Molecular Partners AG to Report Q4, 2024 Results on Mar 07, 2025

Molecular Partners AG Presents Preclinical Proof-Of-Concept for CD3 Switch-DARPin T Cell Engager, Clinical Biomarker Analyses for MP0317 at SITC 2024

Molecular Partners AG has completed a Follow-on Equity Offering in the amount of $20.000004 million.

Molecular Partners AG has filed a Follow-on Equity Offering in the amount of $20.000004 million.

Molecular Partners: A Speculative Bet On Innovative DARPin Technology

Molecular Partners Announces the Debut of their Lead Radio-Darpin Therapy (RDT) Candidate MP0712, Targeting DLL3

Molecular Partners AG Presents Positive Data from Completed Phase 1 Trial of MP0317 (FAP X CD40 DARPin) Monotherapy in Patients with Advanced Solid Tumors At ASCO 2024

Molecular Partners AG Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533's Proposed Mechanism of Action

Molecular Partners AG to Report First Half, 2024 Results on Aug 26, 2024

Molecular Partners AG, Annual General Meeting, Apr 17, 2024

Molecular Partners AG to Report Fiscal Year 2023 Final Results on Mar 14, 2024

Molecular Partners AG Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory AML and AML/MDS At ASH Annual Meeting

Molecular Partners AG Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting

Molecular Partners Ag to Present Initial Data from Ongoing Phase 1/2A Trial of Mp0533 for Patients with Relapsed/Refractory Aml and Aml/Mds At the 65Th Ash Annual Meeting and Exposition

Molecular Partners AG Announces Executive Changes

Molecular Partners Initiates Clinical Study of Trispecific Candidate Mp0533 for the Treatment of Acute Myeloid Leukemia